Observational study to evaluate acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®, Exeltis HealthCare) after six months of use.

Observational study to evaluate acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®, Exeltis HealthCare) after six months of use. - EXELINDA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025993

Enrollment

300

Registered

2021-08-06

Start date

2021-08-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z30

Interventions

Group 1: Only one arm. After 6 months of use with the contraceptive Slinda the users will be asked about the acceptance, tolerability and bleeding profile using a questionnaire. This will be done retr

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Women over 18 years up to 50 years. 2. They use Slinda ® for the approved indication (contraception) and have started treatment at least 6 months before the visit. 3. They shall give informed consent in order to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessment of the effect of Slinda on user acceptance after six months of treatment.	—

Secondary

Measure	Time frame
(a)description of the bleeding profile. (b) tolerability and safety assessment.	—

Countries

Spain

Contacts

Public ContactPedro-Antonio Regidor

Exeltis Healthcare

pedro-antonio.regidor@exeltis.com+491738938132

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026